But the firm, until last year Europe’s most valuable, saw its share price tumble over the past year amid increased competition and disappointing trial results for its next-generation treatments. “The...
Lars Fruergaard Jorgensen, the chief executive of once-highflying Danish drugmaker Novo Nordisk, is stepping down after eight years in the role, the maker of Ozempic and Wegovy drugs announced on...
Novo Nordisk CEO Lars Jorgensen testifies before a Senate Health, Education, Labor, and Pensions Committee hearing on U.S. prices for the weight loss drugs Ozempic and Wegovy, on Capitol Hill...
Novo Nordisk is managing the unusual feat of seeing its stock price rise after reducing its earnings outlook. Source link
